Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 4Recruiting 2Withdrawn 1Unknown 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Rectal Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1

Interventions

Fluorouracil 34Leucovorin 31Oxaliplatin 25Irinotecan 19Capecitabine 13Folfox protocol 11Chemotherapy, Adjuvant 11Cetuximab 11Bevacizumab 9Neoadjuvant Therapy 8XELOX 7Laparoscopy 7Drug Therapy 7Endoscopic Mucosal Resection 5Colonoscopy 5Surgical Procedures, Operative 4Gemcitabine 4Tegafur 3Radiotherapy 3Propofol 3Preoperative Exercise 3Panitumumab 3Fentanyl 3Curcumin 3Colectomy 3Celecoxib 3Aspirin 3raltitrexed 2Surveys and Questionnaires 2Sodium Chloride 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Colonic Neoplasms × Trifluridine × Clear all
NCT03992456 2024-05-21

Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer

Academic and Community Cancer Research United

Phase 2 Unknown
12 enrolled 16 charts
Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡